» 
Arabic Bulgarian Chinese Croatian Czech Danish Dutch English Estonian Finnish French German Greek Hebrew Hindi Hungarian Icelandic Indonesian Italian Japanese Korean Latvian Lithuanian Malagasy Norwegian Persian Polish Portuguese Romanian Russian Serbian Slovak Slovenian Spanish Swedish Thai Turkish Vietnamese
Arabic Bulgarian Chinese Croatian Czech Danish Dutch English Estonian Finnish French German Greek Hebrew Hindi Hungarian Icelandic Indonesian Italian Japanese Korean Latvian Lithuanian Malagasy Norwegian Persian Polish Portuguese Romanian Russian Serbian Slovak Slovenian Spanish Swedish Thai Turkish Vietnamese

definition - Tesofensine

definition of Wikipedia

   Advertizing ▼

Wikipedia

Tesofensine

From Wikipedia, the free encyclopedia

Jump to: navigation, search
Tesofensine
Systematic (IUPAC) name
(1R,2R,3S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane
Identifiers
CAS number402856-42-2
ATC codenone
PubChem11370864
Chemical data
FormulaC17H23Cl2NO 
Mol. mass328.277 g/mol
SMILESeMolecules & PubChem
Pharmacokinetic data
Bioavailability90%
Metabolism20-15% renal. Hepatic: CYP3A4
Half life234 hours
Excretion ?
Therapeutic considerations
Pregnancy cat. ?
Legal statusInvestigatory New Drug
RoutesOral


Tesofensine (NS2330) is a serotonin-noradrenaline-dopamine reuptake inhibitor from the phenyltropane family of drugs, which is being developed for the treatment of obesity.[1] The right to develop and market tesofensine is held by NeuroSearch, a Danish pharmaceutical company.

Contents

History

Tesofensine was originally researched for the treatment of Alzheimer's disease and Parkinson's Disease,[2] but was subsequently dropped from development for these applications after early trial results showed limited efficacy for treatment of Parkinson's,[3][4] but significant weight loss was found in trial participants who were obese.[5]

Tesofensine is now being researched for the treatment of obesity, acting primarily as an appetite suppressant with positive effects on fat oxidation and resting energy expenditure as well.[6] Phase II trials for the treatment of obesity have been successfully concluded, and preparation for Phase III trials is also complete. The final stage trials are scheduled to begin in early 2009 in which the 0.5 mg dose will be tested.[7]

Pharmacology

Tesofensine is a mixed reuptake inhibitor of dopamine, noradrenaline and serotonin,[8] IC50 of 8.0, 3.2 and 11.0nM at the DAT, NAT and 5HTT.[9]

More recently, slightly different IC50 values were published, of (nM) NE 1.7, SER 11, DA 65.[[10] cited in [11]]

Hence, the above IC50's would adequately explain the lack of efficacy in treating Parkinson's disease due to insufficient DRI potency in vivo relative to the SERT and the NET, but retaining SNRI-like anorectic properties (cf. sibutramine).

It also indirectly potentiates cholinergic neurotransmission[12] proven to have beneficial effects on cognition, particularly in learning and memory. Sustained treatment with tesofensine has been shown to increase BDNF levels in the brain, and may possibly have an antidepressant effect.[10]

Tesofensine has a long half-life (234 h),[2] whereas the principle metabolite, M1, has an even longer half-life (374 h). NS2330 is mainly metabolized by cytochrome P450 3A4 (CYP3A4) into its desalkyl metabolite M1.[13][14] M1 is the only metabolite detectable in human plasma and shows the same pharmacological profile as NS2330. In vivo investigations in mice have revealed a five-fold lower potency of the metabolite compared with NS2330.[15]

Clinical trials

Phase IIb trial (TIPO-1) results reported in the Lancet [16] showed levels of weight loss over a 6-month period to be significantly greater than any currently available drugs. Patients lost an average of 12.8 kg on the 1 mg dose and 11.3 kg on the 0.5 mg dose, compared to a 2.2 kg loss in the placebo group. All participants were instructed to be on a mild diet with a 300kcal energy deficit and to gradually increase their physical activity to 30-60mins of exercise per day. The placebo subtracted mean weight losses were 9.2% and 10.6% in the 0.5 mg and 1 mg dose groups, respectively. This is approximately twice the amount of weight loss produced by currently FDA approved weight loss medications.

Neurosearch has also reported interim results [6] from a 48-week open-label extension trial (TIPO-4) in which 140 patients who completed the 24-week Phase IIb trial (TIPO-1) in either one of the active drug cohorts or the placebo group were enrolled, after a 2 month wash-out period, on treatment with the 0.5 mg dose for an additional 48 weeks. 24-week interim results for those who were previously treated with the 0.5 mg dose was a total mean weight loss of 13 to 14 kg over 48 weeks of active treatment and including the weight gain in the 8 week wash out period. Furthermore, TIPO-4 has provided confirmation of the TIPO-1 results as those who were previously treated with placebo, lost approximately 9 kg over 24 weeks with the 0.5 mg dose in the open label study. The full 48 week extension results are expected to be released by the end of 2008.

Side effects

In general, the side effects of tesofensine are similar to currently approved weight loss medications. 20% of the patients in the 1 mg dose cohort withdrew from the trial due to adverse events as compared to 8% in both the 0.5 mg and placebo groups. Side effects such as dry mouth, insomnia, tachycardia, constipation, nausea, diarrhoea, high blood pressure and increases in heart rate were recorded and were generally dose dependent. Furthermore, increased anger and hostility were recorded in the 1 mg dose patients. Both the 0.5 mg and 1 mg doses increased confusion. However, there were statistically significant improvements in overall weight-related quality of life scores in all 3 active drug dose groups as compared to placebo. This was due to improvements in physical function and self-esteem.[16] There is likely to be a significant focus on the psychiatric adverse events in the Phase III trials because of the side effects which have plagued rimonabant, another recently developed weight loss drug that failed to gain FDA marketing approval and was withdrawn from the European market in October 2008.[17] However, the mechanisms of action of rimonabant and tesofensine are different. The 0.5 mg dose of tesofensine has been adopted as the dose to be tested in later trials as it produced weight loss that was not statistically significantly different from the 1 mg dose, but with no statistically significant effect on blood pressure compared to placebo.[18][19]

Chemistry

U.S. Patent 7,544,802 (c.f. "phase transfer catalysis" but crown ether also).

It is possible to reduce an ester to an ether in one pot, without needing to perform classical 2-step sequence.[1][20]

However, this procedure has not yet caught on, and some more time is anticipated before it is enveloped into synthetic methodology.

References

  1. ^ Doggrell, S. (2009). [Expression error: Missing operand for > "Tesofensine--a novel potent weight loss medicine. Evaluation of: Astrup A, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1906-13"]. Expert opinion on investigational drugs 18 (7): 1043–1046. doi:10.1517/13543780902967632. PMID 19548858.  edit
  2. ^ a b Bara-Jimenez, W.; Dimitrova, T.; Sherzai, A.; Favit, A.; Mouradian, M.; Chase, T. (2004). [Expression error: Missing operand for > "Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease"]. Movement disorders : official journal of the Movement Disorder Society 19 (10): 1183–1186. doi:10.1002/mds.20124. PMID 15390018.  edit
  3. ^ Hauser, R.; Salin, L.; Juhel, N.; Konyago, V. (2007). [Expression error: Missing operand for > "Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease"]. Movement disorders : official journal of the Movement Disorder Society 22 (3): 359–365. doi:10.1002/mds.21258. PMID 17149725.  edit
  4. ^ Rascol, O.; Poewe, W.; Lees, A.; Aristin, M.; Salin, L.; Juhel, N.; Waldhauser, L.; Schindler, T. et al. (2008). [Expression error: Missing operand for > "Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study"]. Archives of neurology 65 (5): 577–583. doi:10.1001/archneur.65.5.577. PMID 18474731.  edit
  5. ^ Astrup, A.; Meier, D.; Mikkelsen, B.; Villumsen, J.; Larsen, T. (2008). [Expression error: Missing operand for > "Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease"]. Obesity (Silver Spring, Md.) 16 (6): 1363–1369. doi:10.1038/oby.2008.56. PMID 18356831.  edit
  6. ^ a b "NeuroSearch - Tesofensine". http://www.neurosearch.dk/Default.aspx?ID=118. Retrieved 2008-10-26. 
  7. ^ WebMD - New Drug May Boost Weight Loss Efforts
  8. ^ Jorgen Scheel-Kruger, Peter Moldt, Frank Watjen. Tropane-derivatives, their preparation and use. U.S. Patent 6,395,748
  9. ^ Jorgen Scheel-Kruger, Peter Moldt, Frank Watjen. Tropane-derivatives, their preparation and use. U.S. Patent 6,288,079
  10. ^ a b Larsen, M.; Rosenbrock, H.; Sams-Dodd, F.; Mikkelsen, J. (2007). [Expression error: Missing operand for > "Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine"]. European journal of pharmacology 555 (2-3): 115–121. doi:10.1016/j.ejphar.2006.10.029. PMID 17112503.  edit
  11. ^ Marks, D.; Pae, C.; Patkar, A. (2008). [Expression error: Missing operand for > "Triple reuptake inhibitors: the next generation of antidepressants"]. Current neuropharmacology 6 (4): 338–343. doi:10.2174/157015908787386078. PMID 19587855.  edit
  12. ^ NeuroSearch Update on Tesofensine
  13. ^ Lehr, T.; Staab, A.; Tillmann, C.; Trommeshauser, D.; Raschig, A.; Schaefer, H.; Kloft, C. (2007). [Expression error: Missing operand for > "Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease"]. British journal of clinical pharmacology 64 (1): 36–48. doi:10.1111/j.1365-2125.2007.02855.x. PMID 17324246.  edit
  14. ^ Lehr, T.; Staab, A.; Tillmann, C. (2008). [Expression error: Missing operand for > "Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach"]. British journal of pharmacology 153 (1): 164–174. doi:10.1038/sj.bjp.0707539. PMID 17982477.  edit
  15. ^ Lehr, T.; Staab, A.; Tillmann, C. (2008). [Expression error: Missing operand for > "Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach"]. British journal of pharmacology 153 (1): 164–174. doi:10.1038/sj.bjp.0707539. PMID 17982477.  edit
  16. ^ a b Astrup, A.; Madsbad; Breum; Jensen; Kroustrup; Larsen (2008). [Expression error: Missing operand for > "Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial"]. The Lancet 372: 1906. doi:10.1016/S0140-6736(08)61525-1.  edit
  17. ^ Bloomberg - Sanofi's Acomplia Failure Threatens Obesity Drug Development
  18. ^ Diet drug 'doubles weight loss'. BBC News 22 October 2008
  19. ^ New obesity drug Tesofensine may have huge potential News-Medical.Net 23 October 2008
  20. ^ Sakai, N.; Moriya, T.; Konakahara, T. (2007). [Expression error: Missing operand for > "An efficient one-pot synthesis of unsymmetrical ethers: a directly reductive deoxygenation of esters using an InBr3/Et3SiH catalytic system"]. The Journal of organic chemistry 72 (15): 5920–5922. doi:10.1021/jo070814z. PMID 17602594.  edit

External links

 

All translations of Tesofensine


sensagent's content

  • definitions
  • synonyms
  • antonyms
  • encyclopedia

Dictionary and translator for handheld

⇨ New : sensagent is now available on your handheld

   Advertising ▼

sensagent's office

Shortkey or widget. Free.

Windows Shortkey: sensagent. Free.

Vista Widget : sensagent. Free.

Webmaster Solution

Alexandria

A windows (pop-into) of information (full-content of Sensagent) triggered by double-clicking any word on your webpage. Give contextual explanation and translation from your sites !

Try here  or   get the code

SensagentBox

With a SensagentBox, visitors to your site can access reliable information on over 5 million pages provided by Sensagent.com. Choose the design that fits your site.

Business solution

Improve your site content

Add new content to your site from Sensagent by XML.

Crawl products or adds

Get XML access to reach the best products.

Index images and define metadata

Get XML access to fix the meaning of your metadata.


Please, email us to describe your idea.

WordGame

The English word games are:
○   Anagrams
○   Wildcard, crossword
○   Lettris
○   Boggle.

Lettris

Lettris is a curious tetris-clone game where all the bricks have the same square shape but different content. Each square carries a letter. To make squares disappear and save space for other squares you have to assemble English words (left, right, up, down) from the falling squares.

boggle

Boggle gives you 3 minutes to find as many words (3 letters or more) as you can in a grid of 16 letters. You can also try the grid of 16 letters. Letters must be adjacent and longer words score better. See if you can get into the grid Hall of Fame !

English dictionary
Main references

Most English definitions are provided by WordNet .
English thesaurus is mainly derived from The Integral Dictionary (TID).
English Encyclopedia is licensed by Wikipedia (GNU).

Copyrights

The wordgames anagrams, crossword, Lettris and Boggle are provided by Memodata.
The web service Alexandria is granted from Memodata for the Ebay search.
The SensagentBox are offered by sensAgent.

Translation

Change the target language to find translations.
Tips: browse the semantic fields (see From ideas to words) in two languages to learn more.

last searches on the dictionary :

1948 online visitors

computed in 0.109s

I would like to report:
section :
a spelling or a grammatical mistake
an offensive content(racist, pornographic, injurious, etc.)
a copyright violation
an error
a missing statement
other
please precise:

Advertize

Partnership

Company informations

My account

login

registration

   Advertising ▼